VITESSE

The VITESSE phase 3 study is evaluating an investigational drug patch to learn how well it works in children with peanut allergy. The investigational drug patch is not yet approved by the United States Food and Drug Administration, European Medicines Agency, or any other regulatory agencies. To be eligible to this study, an individual must be: -4 to 7 years of age -Diagnosed with peanut allergy -Currently following a strict peanut free diet This is not a complete list of eligibility criteria. The study doctor will review the full entry criteria for this study with you. Eligible individuals will participate in this study for approximately 58 weeks (about 1 year). To learn more about the VITESSE study for children with peanut allergy, contact: Jenny Gartrell (jennifer_gartrell@med.unc.edu)